Several preclinical studies suggested the use of selective JAK1/2 inhibitors as potential therapy for treatment of CRC, thereby, providing a rationale for randomized controlled trials.17, 18 Also, a subgroup analysis of the randomized, phase 2 RECAP study suggested a survival benefit with ruxolitinib in combination with capecitabine vs. capecitabine alone, in patients with metastatic pancreatic cancer and high CRP levels.9 Altogether, these results suggested a potential benefit of JAK inhibition in solid tumors. The gene discussed is CRP; the disease is colorectal carcinoma.